COMP <GO>
AMRX vs LLY // EV/EBITDA & P/E VALUATION
Amneal Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: AMRX 3
— LLY 11
▲ EV/EBITDA & P/E VALUATION LEADER: AMRX
LAST: $21.51 (+0.75%) • MKT CAP: $7.44B
valuation
21.4x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 83.64% | -46.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 32.36% | -18.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.4x | 36.4x | -15.02 | AMRX | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 2.30% | +1.33 | AMRX | /fcf-yield <GO> |
| Operating Margin | 13.10% | 40.21% | -27.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 31.90% | -29.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 45.51% | -37.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 9.29 | -5.46 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 77.9 | -10.23 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.51 | +0.57 | AMRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 26.3x | +69.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.44B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | LLY REV | AMRX GROSS % | LLY GROSS % | AMRX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $65.18B | 36.9% | 83.0% | $269.9M | $16.81B |
| FY 2024 | $2.79B | $45.04B | 36.5% | 81.3% | $243.2M | $8.82B |
| FY 2023 | $2.39B | $34.12B | 44.0% | 79.3% | $237.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
LLY // BETA 0.51